

Applicants: Graham P. Allaway et al.  
Serial No.: 09/904,356  
Filed: July 12, 2001  
Page 2

### Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims

- 1-25. (Canceled)
26. (Currently Amended) A method of specifically inhibiting fusion of an HIV-1 envelope glycoprotein<sup>+</sup> cell with a CD4<sup>+</sup> cell that fuses with such HIV-1 envelope glycoprotein<sup>+</sup> cell, which comprises contacting the CD4<sup>+</sup> cell with an anti-PM1 monoclonal antibody that (1) inhibits HIV-1 envelope glycoprotein mediated membrane fusion of HeLa-env<sub>JR-FL</sub> to a PM1 cell, but (2) does not inhibit HIV-1 envelope glycoprotein mediated membrane fusion of HeLa-env<sub>LAI</sub> to a HeLa-CD4<sup>+</sup> cell, so as to thereby inhibit fusion of the HIV-1 envelope glycoprotein<sup>+</sup> cell with the CD4<sup>+</sup> cell.
27. (Canceled) ~~The method of claim 26, wherein the antibody is a monoclonal antibody.~~
28. (Currently Amended) The method of claim 26 ~~27~~, wherein the anti-PM1 monoclonal antibody is a chimeric antibody.
29. (Currently Amended) The method of claim 26 ~~27~~, wherein the anti-PM1 monoclonal antibody is a synthetic antibody.
30. (Currently Amended) The method of claim 26, wherein the anti-PM1 monoclonal antibody is an antigen binding fragment of an antibody.
31. (Currently Amended) A method of inhibiting infection of a CD4<sup>+</sup> cell by HIV-1, which comprises contacting the CD4<sup>+</sup> cell with an anti-PM1 monoclonal antibody that (1) inhibits HIV-1 envelope glycoprotein mediated membrane fusion of HeLa-env<sub>JR-FL</sub> to a PM1 cell, but (2) does not inhibit HIV-1 envelope glycoprotein mediated membrane fusion of HeLa-env<sub>LAI</sub> to a HeLa-CD4<sup>+</sup> cell, so as to thereby inhibit infection of the CD4<sup>+</sup> cell by HIV-1.

Applicants: Graham P. Allaway et al.  
Serial No.: 09/904,356  
Filed: July 12, 2001  
Page 3

32. (Canceled) ~~The method of claim 31, wherein the antibody is a monoclonal antibody.~~
33. (Currently Amended) The method of claim 31 ~~32~~, wherein the anti-PM1 monoclonal antibody is a chimeric antibody.
34. (Currently Amended) The method of claim 31 ~~32~~, wherein the anti-PM1 monoclonal antibody is a synthetic antibody.
35. (Currently Amended) The method of claim 31, wherein the anti-PM1 monoclonal antibody is an antigen binding fragment of an antibody.